CAM
BIO icon

Claret Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Claret Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Sell
763
-175
-19% -$49.6K 0.02% 406
2026
Q1 		$261K Hold
938
– – 0.03% 235
2025
Q4 		$284K Sell
938
-2
-0.2% -$624 0.03% 199
2025
Q3 		$264K Sell
940
-13
-1% -$3.54K 0.03% 211
2025
Q2 		$231K Buy
+953
New +$225K 0.03% 376

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Claret Asset Management's BIO Position: Q2 2026 in Review

Claret Asset Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 19% in Q2 2026, selling an estimated $49.6K and leaving 763 shares worth $224K. The position accounts for 0.02% of the portfolio, ranked #406.

Claret Asset Management first reported a position in BIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $284K in Q4 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Claret Asset Management held 763 shares of Bio-Rad Laboratories Class A worth $224K as of Q2 2026.
  • Claret Asset Management sold 175 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $49.6K.
  • Bio-Rad Laboratories Class A made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #406 holding.
  • Claret Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2025 and has held it in 5 quarters since.
  • Claret Asset Management's Bio-Rad Laboratories Class A position peaked at $284K in Q4 2025.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.